Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Quantum BioPharma Ltd C.QNTM

Alternate Symbol(s):  QNTM

Healthcare
Quantum BioPharma Ltd. is a Canada-based biopharmaceutical company. The Company is engaged in building a portfolio of assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. (Lucid), it is focused on the research and development of its lead compound, Lucid-MS, which is a patented new chemical entity to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis. Its unbuzzd beverage is a proprietary formulation of vitamins and minerals to help with liver and brain function for the purposes of relieving the effects of alcohol consumption and restoring a normal lifestyle. It maintains a portfolio of strategic investments through its wholly owned subsidiary, FSD Strategic Investments Inc., which represents loans secured by residential or commercial property.


CSE:QNTM - Post by User

Quantum BioPharma Ltd > New Press Release - Goldman Small Cap Research Publishes New Research Report on FSD Pharma, Inc.
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(83)
•••
Comment by Bigmac4000on Aug 11, 2024 4:40pm
122 Views
Post# 36173662

RE:RE:New Press Release - Goldman Small Cap Research Publishes New Research Report on FSD Pharma, Inc.

RE:RE:New Press Release - Goldman Small Cap Research Publishes New Research Report on FSD Pharma, Inc.
lscfa wrote: Goldman remarked, "Our forecasts assume full product sales of UNBUZZD™ will grow from $42M in 2023 to $138.7M in 2025, from which HUGE is entitled to royalties. 

Ok so you just posted a complete false lie. Sales in 2023? Wait lol what?!   
Please what sales did they have in 2023? It's 7 months into 2024. Not a product to be seen. Where do you come up with this garbage..  you just made them look even more stupid then they do themselves lol. I'm hoping you don't get paid for this junk. 
Don't forget , buy into this mess and you will be involved in a 65-1 RS . Best of luck 
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities